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Objectives: To assess anti-inflammatory activity on acute and sub-acute 
inflammation of most promising compound of a synthetic novel indole 
derivative and elucidating of mechanisms of action  
Methods:  Four synthesized compounds (m1k, m2k, m3k and m4k) and 
indomethacin were docked into COX2 enzyme using MOE software and the 
most promising compound was selected, then M1k was investigated for 
further in vivo anti-inflammatory activity on acute inflammatory by 
carrageenan induced rat paw edema in Wistar rats at the dose of 33.33 
mg/kg and 66.66 mg/kg, i.p, then M1k was investigated for further in vivo 
anti-inflammatory activity on sub-acute inflammatory by cotton pellet-
induced granuloma at dose 66.66 mg/kg, i.p,  and in vitro anti-inflammatory 
activity was evaluated using Heat-induced hemolysis at doses ranging from 
[100, 200, 300 and 500 μg/ml]. Then, the ulcerogenecity of M1k was 
addressed by in vivo modelling in Wistar rats at the dose 66.66 mg/kg, PO; 
ulcer Index, severity Index, and % of total ulceration were measured.  
Results: M1k showed greater affinity to COX2 (Affinity energy =-14.56 
kcal/mol), on molecular docking study using MOE software, the m1k 
showed greater significant effect (P<0.001) reduction in paw edema against 
carrageenan on carrageenan induced rat paw edema method, the m1k 
showed moderate anti-inflammatory activity percentage (77.2%) on 
carrageenan induced rat paw edema method, the m1k showed greater 
significant effect (𝑃 < 0.001) on reduced the granuloma formation on cotton 
pellet-induced granuloma method, the m1k showed greater anti-
inflammatory activity percentage (60.93   %(  on cotton pellet-induced 
granuloma method, the m1k exhibited greater significant effect (P < 0.001) 
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in inhibiting the heat-induced hemolysis of erythrocyte membrane on 
membrane stabilizing activity assay, the m1k showed greater anti-
inflammatory activity percentage (98.66%) on membrane stabilizing activity 
assay, the m1k exhibited higher ulcerogenic  liability (ulcer index =15) on 
acute ulcerogenesis assay. 
Conclusion: Findings from this study clearly suggest that the m1k possess 
significant anti-inflammatory properties in both acute and chronic 


















Arabic Abstract المستخلص 
 االهداف:
 كٙ( انًصُغ يعًهٛبَ 1ٔنهًشكت) اوانذبد شجّ رٓذف انذساسخ نزقٛٛى انُشبط انًضبد نالنزٓبة انذبد ٔ  
.رٕضٛخ انٛخ عًهّ  
 منهجية اجراء الدراسة:
عٍ  2نهًسزقجم اَضٚى انكٕكس  كٙ(4كٙ او3كٙ او2كٙ او1) اويذبكبح اسرجبط جضئٛبد انًشكجبد  
،ٔ  طشٚق اسزخذاو ثشَبيج  انًذبكبح )او أ ا٘( فٙ انذبسٕة ٔ اخزٛبس اقٕاْب اسرجبطب ثبنًسزقجم
نزٓبة عٍ طشٚق دقٍ يبدح انكٛشاجُبٌ رذذ انجهذ فٙ قذو اسجم انفئشاٌ انًعًهٛخ ٔ اسزذذاس اال
اسزذذاس االنزٓبة عٍ طشٚق  صساعخ كشاد انقطٍ رذذ انجهذ فٙ انًُطقخ انسفهٗ يٍ ثطٍ انفئشاٌ 
انًعًهٛخ ٔ طشٚقخ صجبرٛخ غشبء كشٚبد انذو االدًش ٔ نذساسخ انزقشدبد انًعذٚخ انذبدح نهًشكت ) 
كٙ(1او  
 ٔانًضبد نالنزٓبة ٔكزنكانًذبكبح  كذٔاء قٛبسٙ )يشجع( نذساسخ  اَذٔيٛسبصسٍ  رى اسزخذاو عقبس
.رذذ انذساسخ نهًشكت ّنذساسخ انزقشدبد انًعٕٚ  
 النتائج:
عٍ طشٚق اسزخذاو ثشَبيج   2كٙ( اَجزاة عبنٙ رجبِ انًسزقجم اَضٚى انكٕكس 1ظٓش انًشكت ) اوأ 
كٛهٕ كبنٛش٘/يٕل( ، اظٓشانًشكت  – 14.56)طبقخ االسرجبط =     انًذبكبح )او أ ا٘( فٙ انذبسٕة 
 انُبرج عٍ طشٚق اسزذذاس االنزٓبةكٙ(  رأصٛش عبنٙ جذا ثشكم ٔاضخ عهٙ نٕريخ كف انقذو 1) او
كٙ(  َسجخ عبنٛخ يضبد نالرٓبة  1، كًب اظٓشانًشكت ) او (0.001دقٍ يبدح انكٛشاجُبٌ   )ع > 
ٔ  كًب اظٓشانًشكت )  ،  %( انُبرج يٍ اسزذذاس االنزٓبة عٍ طشٚق دقٍ يبدح انكٛشاجُب77.2ٌ)
انٕسو انذجٛجٙ عٍ طشٚق صساعخ كٕسٚبد  كٙ(  رأصٛش عبنٙ جذا ثشكم ٔاضخ عهٙ خفض رك1ٌٕاو
نالرٓبة  يضبد ٙ(  َسجخ عبنٛخك1ٔ  كًب اظٓشانًشكت ) او  ،(0.001انقطٍ فٙ يُطقخ انجطٍ  ع > 
ٔ  كًب  ،%(60.93شجّ انذبد انًسزذش عٍ طشٚق صساعخ كٕسٚبد انقطٍ فٙ يُطقخ انجطٍ )
كٙ(  رأصٛش عبنٙ جذا ثشكم ٔاضخ  ثبسزخذاو طشٚقخ صجبرٛخ غشبء كشٚبد انذو 1اظٓشانًشكت ) او
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%(  ثبسزخذاو 98.66ة )كٙ( َسجخ عبنٛخ جذا يضبد نالرٓب1ٔ اظٓش  ) او ، (0.001االدًش   )ع > 
  
كشفذ َزبئج  ،طشٚقخ صجبرٛخ غشبء كشٚبد انذو االدًش عهٗ يسزٕٖ االَسجخ )خبسج جسى انذٕٛاٌ(
.نّ رأصٛش يٓٛج ٔ يقشح نهجذاس كٙ(1انًشكت ) اودساسخ انزقشدبد نهًعذح اٌ   
:الخاتمة  
ًٚزهك ثشكم كجٛش خصبئص كٙ( 1ثشكم ٔاضخ اٌ انًشكت ) او رؤشٛشانُزبئج يٍ ْزِ انذساسخ 
انذبد ٔ نّ رأصٛش يٓٛج نغشبء انًعذح انًخبطٙ.شجّ يضبد نالنزٓبة انذبد ٔ   
 




























1. Introduction and Literature Review 
1.1. Introduction  
Inflammation is an essential response to tissue injuries that occur due to 
physical, chemical or biological insults (1, 2, & 3). The classic signs of 
inflammation are heat, redness, swelling, pain, and loss of function. These are 
manifestations of the physiologic changes that occur during the inflammatory 
process. The three major components of this process are changes in the caliber 
of blood vessels and the rate of blood flow through them, Increased capillary 
permeability and exudation (2, 3). Both acute and chronic inflammations play 
essential roles in the restoration of homeostasis. However, the mechanisms by 
which activated leukocytes combat germs and tumor cells and eliminate tissue 
debris in areas of inflammation lead to the production of oxidants and/or of 
cytotoxic cytokines (1). Several gastrointestinal, cardiovascular, neurological 
and psychiatric disorders show involvement of pro-inflammatory mediators 
acting as culprits in the inflammatory process. Categorically inflammation 
process can be divided into three distinct phases, the first phase characterized 
by increased vascular permeability and exudation of fluids namely the acute 
phase followed by the second phase involving infiltration of leuckocytes and 
granuloma formation called as the sub-acute phase ultimately followed by the 
third and last phase of chronic inflammation typically characterized by 
regulated production of pro and anti-inflammatory mediators like the TNF-α, 
(IL)-1β and IL-6,chemokines, and inducible enzymes (3). The pro-
inflammatory cytokines tumor necrosis factor alpha (TNF-a) and interleukin 
1-beta (IL-1b) are small molecular weight proteins secreted mainly by the 
immune cells. They act as important mediators involved in the 
pathophysiology of several chronic inflammatory diseases, including 
2 
 
rheumatoid arthritis (RA), inflammatory bowel disease, septic shock, and 
osteoporosis (4). Cyclooxygenases are the endogenous enzyme system mainly 
responsible for cellular prostaglandin biosynthesis and catalyze the reactions 
in which Arachidonic acid (AA) is converted to prostaglandin H2 (PGH2). 
COX exists in two isomeric forms such as COX-1and COX-2. Among the two 
isomeric forms, COX-2 mainly acts as target of commonly used anti-
inflammatory drugs (5). The anti-inflammatory activity of various isatin 
semicarbazide derivatives were evaluated by carrageenan-induced paw edema 
test in rats. The compound containing trifluoro methyl substituent displayed 
significant anti-inflammatory activity at the dose of 10 and 20 mg/kg and one-
third of ulcer index compared to the reference drug diclofenac and aspirin (6).. 
Indole substituted in the 3rd position with various chalcones, pyrazolines and 
azo-compounds were evaluated for their anti-inflammatory activity. The 
compound showed a maximum of 47% anti-inflammatory activity among the 
compounds. It also exhibited less ulcerogenic liability than the standard drug 
(7). The therapeutic targeting of the inflammatory response is an important 
field of study (8). 
1.2. Pharmacological Review of Anti-inflammatory Agents.   
1.2.1. Review on Inflammation and Anti-inflammatory Agents.   
The inflammation process is part of the human defense system and the 
immune system’s response against foreign pathogens and tissue damage (7). 
However, the primary purpose of inflammation is to restore homeostasis and 
hence constitute a protective biological response to injuries (9). An 
uncontrolled inflammation process is a unifying component in many chronic 
diseases including atherosclerosis, asthma, rheumatoid arthritis (RA) and type 
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2 diabetes (10). Inflammation may be divided into acute inflammation and 
chronic inflammation. 
1.2.1.1. Acute Inflammation 
In the early stages of an inflammatory response, the resident cells (tissue 
macrophage, dendritic cells and epithelial cells) start producing inflammatory 
mediators, which subsequently increase vessel permeability, vasodilation, 
blood flow, edema and the recruitment of leukocytes (7, 9). Polymorphonuclear 
leukocytes (PMNs) are the first cells which extravasate into inflamed tissue, 
and are an important host for the production of the inflammatory mediators, 
including cytokines, chemokines, lipid mediators and growth factors. An 
injurious stimulus will trigger the above-mentioned biochemical responses in 
the body, causing the classic signs of acute inflammation, i.e. swelling, 
redness, heat and pain (9) .If resolution of the underlying initiating factor is not 
achieved, the acute inflammation may develop into a chronic state of 
inflammation ( 11,12) . 
1.2.1.2. Chronic inflammation 
Chronic inflammation is defined by the accumulation of lymphocytes, 
macrophages and plasma cells in tissues, which is collectively called the tissue 
response, the vascular response involves transmigration of lymphocytes and 
monocytes, and leakage of antibodies into the affected tissue, monocytes 
“mature” into macrophages, which produces pro-inflammatory mediators (12). 
These mediators can regulate the production of collagen in tissues by the 
activation of fibroblasts. Another interesting effect of these pro-inflammatory 
mediators is the activation of other macrophages and lymphocytes, which 
further on perpetuates the inflammatory response (7,12) Chronic inflammatory 
processes can develop into cardiovascular diseases, rheumatoid arthritis (RA), 
periodontal diseases, Alzheimer’s disease, asthma and diabetes (7) . 
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1.2.1.3. Prostaglandin biosynthesis 
Prostanoids (PG’s) are end products of fatty acid metabolism produced via the 
COX pathway. PG’s have long been known to behave as important 
physiological and pathological mediators implicated in a number of 
therapeutic areas of interest including inflammation, pain, pyrexia, cancer, 
glaucoma, male sexual dysfunction, osteoporosis, cardiovascular disease, 
labor and asthma (13). AA an unsaturated 20-carbon fatty acid embedded in 
cell membranes as a phospholipid ester, is the precursor for PG synthesis 
(Figure 1.1). In response to a wide variety of stimuli, free AA is released 
which is subsequently converted via COX, lipoxygenase (LOX) and 
cytochrome P450 enzyme catalysis to various lipid mediators known 
collectively as eicosanoids (14). In the COX pathway, the two known COX 
isoforms catalyse the first committed step in the biosynthesis of PG’s, 
thromboxanes (TxA) and other eicosanoids (13, 14) .The production of these 
eicosanoids is dependent on the availability of AA. The release of AA from 
membrane phospholipids is mediated by either secretory (sPLA2) or 
cytoplasmic (cPLA2) phospholipases. Once AA is released, the COX 
isoforms catalyze two sequential reactions. The initial COX reaction converts 
AA to prostaglandin G2 (PGG2). The subsequent peroxidase (POX) reaction 
reduces PGG2 to prostaglandin H2 (PGH2) which is then converted by 
various cell specific isomerases and synthases to produce five biologically 
active primary PG’s that include prostaglandin D2 (PGD2), prostaglandin E2 
(PGE2), prostaglandin F2α (PGF2α), prostacyclin (PGI2) and thromboxane 
A2 (TxA2) as illustrated in Figure (1.1). These products act as secondary 
messengers by interacting with prostanoid G-protein coupled receptors and 






Figure 1-1: Representative biosynthetic pathway of prostaglandin (PG) 




1.2.1.4. COX isoforms and inflammation 
Traditional NSAIDs prescribed to control joint pain and treat inflammatory 
conditions such as Rheumatoid arthritis (RA) and Osteoarthritis (OA) produce 
their anti-inflammatory and analgesic effects by nonselective inhibition of 
COX activity. During the inflammatory process, the COX-1 mRNA and 
protein activity do not change whereas a dramatic increase in COX-2 levels 
occurs leading to increased production of pro-inflammatory PGs. The GI side 
effects associated with traditional NSAIDs are due to the inhibition of gastro-
protective PGs synthesized via the COX-1 pathway (15, 16). The expression of 
COX-2 has been studied extensively in animal models of inflammation which 
provided strong evidence that induction of COX-2 enzyme is associated with 
inflammation. The COX-1 enzyme does not appear to be affected by the 
inflammatory process since similar levels of mRNA and protein are detected 
in both normal and inflamed tissue in animal models. PGs such as 
prostaglandin E2 (PGE2) and prostacyclin (PGI2) produced via the COX-2 
pathway magnify the degree of inflammation initiated by other mediators of 
inflammation such as histamine and bradykinin leading to increased vascular 
permeability and edema (17-18).  
1.2.1.5. Cyclooxygenases functions in the human body: 
In humans and other species, it has been shown that COX-1 but not COX-2 is 
expressed constitutively throughout the GI tract (19). PGs such as prostaglandin 
E2 (PGE2) and  prostacyclin (PGI2) produced by COX-1 are known to exhibit 
cytoprotective effects on the GI mucosa by reducing gastric acid secretion by 
parietal cells in the stomach, increase mucosal blood flow, and stimulate the 
release of viscous mucus. Selective COX-2 inhibitors are efficient anti-
inflammatory agents with less GI toxicity due to their selective inhibition of 
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COX-2 and sparing action on COX-1. However, there are reports of 
constitutive COX-2 expression in healthy human and rabbit GI mucosa (20).It 
has also been reported that during the GI ulcer formation process, COX-2 may 
be induced and that it could play a role in the GI healing (21) Clinical trials 
indicate short term GI safety benefits occur with selective COX-2 inhibitors 
compared to traditional NSAID therapy (22). PGs regulate vascular tone and 
normal blood flow thereby maintaining renal function (23). Studies using 
animal models of renal diseases, and patients with congestive heart failure, 
liver cirrhosis or renal insufficiency have shown that as prostaglandin E2 
(PGE2) was primarily responsible for maintaining normal kidney function (24). 
The COX-2 enzyme is involved in normal renal development and COX-2 
deficient mice develop severe nephropathy (25). Studies have shown that 
NSAID-induced sodium retention in healthy and elderly patients is mediated 
by the inhibition of COX-2, whereas a decreased glomerular filtration rate is 
associated with inhibition of COX-1. These studies confirm that both COX 
isoforms are involved in renal physiology (26). Recent studies have indicated, 
among a group of current selective COX-2 inhibitors, that rofecoxib is 
associated with increased renal and arrhythmia risks (27). It is well known that 
the COX-1 isoform is constitutively expressed in platelets and is responsible 
for the formation of pro-aggregatory thromboxane A2 (TxA2). In contrast, the 
synthesis of anti-aggregatory prostacyclin (PGI2) in endothelial cells is 
primarily catalyzed by COX-2 (28). The argument was that PGI2 is a 
vasodilator and a potent inhibitor of platelet aggregation produced by COX-2 
at the sites of inflammation. Although selective COX-2 inhibitors have no 
effect on thromboxane A2 (TxA2) production, by decreasing prostacyclin 
(PGI2) production, selective COX-2 inhibitors may tip the natural balance 
between prothrombotic TxA2 and anti-inflammatory  prostacyclin (PGI2) that 
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could potentially increase the possibility of a thrombotic cardiovascular event. 
In addition, there are other indications of a protective role for prostaglandin 
E2 (PGE2) and prostacyclin (PGI2) derived from the COX-2 pathway 
pertaining to oxidative damage (29). The use of NSAIDs has been associated 
with a delay in the onset of Alzheimer’s disease (AD) in high risk families (30). 
Since AD is associated with inflammatory conditions in brain, the protective 
effect provided by NSAIDs is consistent with their anti-inflammatory activity. 
Initially, selective COX-2 inhibitors were touted as a potential therapy to treat 
AD since long term treatment using NSAIDs leads to GI toxicity (31). 
However, current data regarding the use of selective COX-2 inhibitors in AD 
is conflicting. For example, a recent study has shown that the selective COX-
2 inhibitor rofecoxib failed to slow cognitive decline in patients with mild-to-
moderate AD (32). 
1.2.2. Anti-inflammatory Agents.   
1.2.2.1. Non-Steroidal anti-inflammatory drugs (NSAIDs) 
NSAIDs are among the most commonly used drugs worldwide, used by more 
than 30 million people every day. More than 111 million prescriptions are 
written for NSAIDs in the USA annually, and they account for approximately 
60% of the USA over-the-counter (OTC) analgesic market (33).  
1.2.2.1.1. NSAIDs classification, COX selectivity and efficacy 
NSAIDs can be classified on the basis of their chemical and 
pharmacological properties, and COX selectivity. On the basis of their 
chemical structure, they are classified as (34). 
1. Salicylic acid derivates: acetylsalicylic acid (aspirin), sulfosalazine 
2. Para-aminophenol derivates: acetaminophen (paracetamol) 
3. Indole and indene acetic acids: indomethacin, etodolac, sulindac 
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4. Hetero-aryl acetic acids: diclofenac, ketorolac, tolmetin 
5. Aryl-propionic acids: ibuprofen, ketoprofen, flurbiprofen, naproxen, 
fenoprofen, oxaprozin aceclofenac, fenclofenac 
6. Anthranilic acids (fenamates): mefenamic acid, meclofenanic acid 
7. Enolic acids (oxicam): piroxicam, tenoxicam, meloxicam 
8. Alkanones: nabumetone 
9. Pyrazolidinediones: phenylbutazone, oxyphenylbutazone 
10. Diarylheterocycles (selective COX-2 inhibitors): celecoxib, rofecoxib, 
valdecoxib, lumiracoxib, parecoxib, eterocoxib. 




Poorly selective NSAIDs that fully 
 inhibit both COX-1 and 
 COX-2 (<5-fold COX-2 selectivity)   
Ibuprofen, diclofenac,  
aspirin, piroxicam,  
naproxen   




NSAIDs capable of inhibiting both 
 COX-1 and COX-2 with  
a preferential selectivity toward COX-2 








NSAIDs that strongly inhibit COX-2 but 
 only weakly inhibit COX-1  
(>50-fold COX-2 selectivity)   
Rofecoxib,  
NS-398   
Group 4  
 
NSAIDs that seem to be only weak  
inhibitors of both COX-1 and COX-2   
Sodium salicylate, 




1.2.2.1.1. Mechanism of action of NSAIDs 
Despite their structural diversity, all NSAIDs inhibit COX. The mechanism 
of action of NSAIDs was discovered by Vane, but it was only fully explained 
after Simmons reported the presence of COX-2 (36). PGs are the end products 
of fatty acid metabolism, and are produced via the COX pathway. They have 
long been known to act as major physiological and pathological mediators in 
a number of therapeutic areas including inflammation, pain, pyrexia, cancer 
and neurological diseases (37). 
1.2.2.1.2. Pharmacodynamics and Pharmacokinetics of NSAIDs 
The major therapeutic actions of NSAIDs are primarily enacted by their 
ability to block certain PGs synthesis through the cyclooxygenase enzymes 
(COX-1 and COX-2) inhibition. COX-1 produces prostaglandins and 
thromboxane A2 which control mucosal barrier in GI-tract, renal homeostasis, 
platelet aggregation and other physiological functions. COX-2 produces PGs 
that related to inflammation, pain and fever. COX-1 is expressed in normal 
cells, while COX-2 is induced in inflammatory cells (38). COX-2 inhibition 
most likely represents the desired effect of NSAIDs’ anti-inflammatory, 
antipyretic and analgesic response; while COX1 inhibition plays a major role 
in the undesired side effects such as GI and renal toxicities. Most NSAIDs are 
well absorbed in the gastrointestinal tract and have high bioavailability. Some 
drugs such as diclofenac undergo hepatic first-pass metabolism which resulted 
in the reduction in bioavailability. While some drugs such as sulindac and 
parecoxib are pro-drugs and need hepatic metabolism to become their active 
metabolites (sulindac sulfide and valdecoxib, respectively). NSAIDs are 
highly bound to plasma proteins. NSAIDs are usually metabolized in the liver 
and excreted in the urine. Common NSAIDs drug have a variable half-life; 
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they can be anywhere from 0.25-0.3 hours such as aspirin or 45-50 hours such 
as piroxicam (39). 
1.2.2.1.3. Adverse reactions  
Peptic ulcer diseases (PUD) cause major complications, such as upper 
gastrointestinal bleeding (about 70% of cases) (40). 
The greatest common adverse proceedings associated with oral NSAID 
treatment are those affecting gastrointestinal system (41), about 30 to 50% of 
NSAID users suffering from ulcerations (42). 
A recent study exhibited that 86.6% were at increased gastrointestinal risk and 
22.3% were considered at high risk for gastrointestinal effects (41). 
NSAIDs postponement ulcer curative by reducing prostaglandin, which plays 
a critical role in mucosal maintenance and protection (43). 
Notwithstanding their extensive use and valuable effects, NSAIDs increase 
the risk of gastroduodenal ulcers, the consequences of which can sometimes 
be life-threatening bleeding or perforation (44). 
1.2.2.2. Indole derivatives 
1.2.2.2.1. Pharmacological Activities of Indole Derivatives 
1.2.2.2.1.1. Anti-Inflammatory Activity 
Ashok Kumar et, al (45) synthesized a series of novel substituted indole 
derivatives and were evaluated for their in vitro anti-inflammatory activity. It 
was found that the compound 2-(p-chlorophenyl)-1-[4-(2-(p-chorophenyl)-4-
oxo-thiazolidin-3-yl]-5-mercapto[1,2,4,]-trizole-3-yl methyl]-3[4,6-dibromo-
2-carboxyphenyliminomethyl]-5-methoxyindole had shown prominent anti-








Dubey et, al (46) synthesized a series of novel [2-(3-oxo-3,4-dihydro-2H-
benzo[1,4]oxazin-6-carbonyl)-1H-indol-3yl]aceticacid derivatives and 
evaluated for their anti-inflammatory activity. It was found that the 




Thirumurugan prakasam et, al (47) synthesized a various 2-(1H-indol-3-yl)-6-
methoxy-4-pentylpyridine-3,5-dicarbonitrile derivatives and was screened for 







1.2.2.2.1.2. Analgesic Activity 
Rapolu Manish et, al (48) synthesized a series of novel 2-methyl-1H-indole-3-
carboxylic acid[2-(2-substitutedphenyl)-4-oxo-thiazolidin-3-yl]amide 
derivatives and evaluated for their analgesic activity by using hot plate latency 
and acetic acid induced writhing test. Most of the compounds which are 
having two hydroxyl group and one methoxy group on the phenyl ring had 
shown excellent analgesic activity. 
 
Figure 1-5: 2-methyl-1H-indole-3-carboxylic acid [2-(2-
substitutedphenyl)-4-oxo-thiazolidin-3-yl] amide 
Kumar Ashok et, al (49) synthesized a series of novel substituted indole 
derivatives and were evaluated for their analgesic activity. It was found that 
the compound 2-(p-chlorophenyl)-1-[4-(2-(pchorophenyl)- 4-oxo-
thiazolidin-3-yl]-5-mercapto[1,2,4,]-trizole-3-yl-methyl]-3[4,6-dibromo-2-
carboxyphenyliminomethyl]-5-methoxyindole had shown prominent 




Figure 1-6: 2-(4-Chlorophenyl)-1-{4'-(4-chlorobenzylidine) amino-5'-(2-
aminothiazol-4-ylthio)-[1',2',4']-triazol-3'-yl-methyl-3-(4",6"-dibromo-
2"-carboxyphenyliminomethyl }-5-methoxy-indole 
1.2.2.2.1.3. Antimicrobial Activity 
Mehta DS et, al (50) synthesized a series of novel 1-aryl-2 methyl-3-
carboethoxy-5-hydorxy indole derivatives and evaluated their antimicrobial 
activity against B. mega , B. subtilis bacteria.10 
 
                 A                                                                           B 
Figure 1-7: A (7-azaindole-3-acetamidoxime), B (7-azaindole-1-
acetamidoxime) 
Kumar Dharmendra et, al (51) synthesized 5-chloro-2-phenylindole derivative 
and shown significant activity against P. aeruginosa and S. thermonitrificans 




Figure 1-8: 5-chloro-2-phenylindole 
Hiari-Al M. Yusuf et, al (52) synthesized 3-(4-trifluoromethylphenyl)indole 
derivative and were evaluated for their antimicrobial activity against 
Escherichia coli and Staphylococcus bacteria. All of the synthesized 




Figure 1-9: 3-(4-trif luoromethylphenyl)indole 
1.2.2.2.1.4. Anticonvulsant Activity 
Sharma Prince P et, al (53) synthesized a series of various 3-(1,3-benzothiazol-
2-ylimino)-1,3-dihydro-2H-indol-2-one derivatives and it was found that 
compounds had shown prominent anticonvulsant activity. 
 
Figure 1-10: 3-(1,3-benzothiazol-2-ylimino)-1,3-dihydro-2H-indol-2-one 
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1.2.2.2.1.5. Antitumor Activity 
Farghaly AR (54) synthesized a series of novel [1-(4-methoxybenzyl)indol-3 
yl](1H-pyrazol-1-yl)methanones and 1-(1-(4-methoxybenzyl)-1H-indole-3-
carbonyl)-3-subsituted-1H-pyrazol-5 (4H)-one derivatives and all 
synthesized target compounds were tested in vitro for antitumor activity using 
the Alamar Blue assay on a panel of five human tumor cell lines. The 
cytotoxicity was evaluated on five different cell lines, cervix cancer 
(KB/HELA), ovarian carcinoma (SKOV-3), brain cancer (SF-268), non-
small-cell lung cancer (NCl-H460) and adenocarcinoma colon cancer 





SAWY-EL Eslam et, al (55) synthesized a series of novel 1-benzyl-3-
heterocyclicindole and 1-benzoyl-3-heterocyclicindole derivatives. All the 
synthesized compounds were initially screened for in vitro anticancer activity 
at a concentration of 10–7 mol L–1 against two human cancer cell lines, 
OVCAR3 and BG-1, compared to vitamin D [1,25(OH)2D3] (10–7 mol L–1) 
using the MTT assay. The growth inhibition action of the tested compounds 
was reported after 24 and 48 h for each cell line. Some compounds were found 
to be the most cytotoxic, with growth inhibition of 98.5 ± 1.2, 97 ± 0.6 and 
96.14 ± 0.5 %, respectively, after treatment for 24 h and 99.9 ± 1.5, 98.6 ± 0.6 
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and 97.6 ± 0.6, respectively, compared to vitamin D (43.9 ± 7.8 and 59.8 ± 





                  A                                        B 
Figure 1-12: A (1-[(1-benzyl indol-3-yl) carbomethyl]-2-
thioxoimidazolidine-4-one, B (1-[(1--benzoyl indol-3-yl) carbomethyl]-2-
thioxoimidazolidine-4-one). 
1.2.2.2.1.6. Antifungal Activity 
Mehta DS et, al (56) synthesized a series of 1-aryl-2-methyl-3-carbethoxy-5-
hydroxyindole derivatives and evaluated their antifungal activity against A. 
awamori and A. arogens. Some compounds had shown remarkable antifungal 
activity. 
 
Figure 1-13: 1-aryl-2-methyl-3-carboethoxy-5-hydroxy indole 
Pandeya et, al (57) synthesized Schiff bases of isatin and 5-methyl isatin with 
sulphadoxine and were evaluated for their in vitro antifungal activity against 
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various fungal strains viz. Candida albicans, Candida neoformis, 
Histoplasma capsulatum, Microsporum audounii and Trichophyton 
mentagrophytes. It was found that the piperidino methyl compounds have 
shown prominent antifungal activity. 
 
Figure 1-14: R'= -CH3, R=-N (CH3)2, N (C2 H5)2, 1-piperidyl, 1-
pyrrolidinyl, 4-morpholinyl, etc. 
1.2.2.2.1.7. Antihypertensive Activity 
 Bell MR et, al (58) synthesized a series of novel 7-azaindole-3-acetamidoxime 
and 7-azaindole-1-acetamidoxime and evaluated for its antihypertensive 
activity. These compounds have shown prominent antihypertensive 
properties. 
 
         A                                               B 
Figure 1-15: A (7-azaindole-3-acetamidoxime) and B (7-azaindole-1-
acetamidoxime) 
1.2.2.2.1.8. Antiviral Activity 
Wang Dun et, al (59) synthesized various 2-arylthiomethyl-4-tertiary amino 
methyl substituted derivatives of 6-bromo-3-ethoxycarbonyl-5-
hydroxyindole and evaluated there in vitro antiviral activity against 
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laboratory-passaged isolates of human influenza A3 and respiratory syncytial 
virus (RSV) respectively in MDCK cell culture and HeLa cell culture with 
virus cytopathic effect assay in comparison with amantadine and Abidol. The 
50% inhibitory concentration (IC50) and the minimum inhibitory 
concentration (MIC) for the tested compouds against the above two virus were 
calculated with Reed and Muench Method and therapeutic index (TI) was 
obtained. Some compounds had shown significant antiviral activity. 
 
Figure 1-16: 3-ethoxycarbonyl-6-bromo-5-hydroxyindole 
1.2.2.2.1.9. Anti-Proliferative Activity 
 Narayana B et, al (60) synthesized a series of novel 2-[5-(aryl)-1,3,4-
oxadiazol-2-yl]-4/5-6/7-nitro-1H-indole derivatives and evaluated for their in 
vitro anti-proliferative activity.20 
 
Figure 1-17: 2-[5-(phenyl)-1,3,4-oxadiazol-2-yl]-4/5/6/7-nitro-1H-indole 
1.2.2.2.2. Indoles in Medicinal Chemistry 
Indole is an aromatic heterocyclic compound that has a bicyclic structure. It 
is an accepted constituent of fragrances and the precursor to many 
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pharmaceuticals. One of the oldest and most reliable methods for synthesizing 
substituted indoles is the Fischer indole synthesis developed in 1883 (61). 
Indoles are present in many important biological compounds. Tryptophan is a 
significant indole derivative while serotonin and melatonin are biochemically 
active indole molecules. There are also many indole alkaloid derivatives 
found in nature. The plant hormone Auxin contains indol- 3-acetic acid. 
Furthermore, there are many important indole derivatives used in treatment. 
The anti-inflammatory drug indomethacin, the beta-blocker pindolol, and the 
naturally occurring hallucinogen dimethyltryptamine are some of the 
important indole derivatives. Indole derivatives represent many important 
classes of therapeutic agents in medicinal chemistry such as anticancer (62), 
antioxidant (63), anti-rheumatoidal (64), and anti-HIV (65). Studies showed that 
some of the 2-phenylindole (2PI) sulfamates are inhibitors of steroid sulfatase 
with antiproliferative activity in breast cancer cells (66). Some of the sulfur 
containing 2PI derivatives show in vivo antineoplastic and antiestrogenic 
activity (67). Furthermore, some indole derivatives, such as melatonin and 
serotonin, influence many important biochemical processes. They act as 
antioxidant and play an important role in the immune system (68). 
1.2.2.4. Structure–activity Relationships (SAR) of Indole Derivatives as 
Potential Anti-inflammatory Agents 
In order to design any structure with pyrrole moiety or its fused form indole, 
vital considerations must be taken to ensure its anti-inflammatory activity (69). 
First, the structure should consist of an acidic moiety (carboxylic acid, enols, 
ester etc.) attached to a planar, aromatic functional group (appears to correlate 
with the double bond of AA),314-benzodioxine or pyrrole nucleus are 
described. Several derivatives, including (S and a polar linking group (which 
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attaches the aromatic ring to a lipophilic group in AA) (70). Addition of a 
second hydrophobic ring not coplanar with the original aromatic ring, was 
found to enhance activity (71), this second hetero-aromatic ring or heterocyclic 
ring was believed to provide the necessary geometry to attach to AA.81 
Taking indomethacin as an example, it was found that N-benzoyl moiety 
seems to play an important role for the COX-1 activity of indomethacin.32 If 
the latter moiety is replaced with any other bulkier N-substituents, efficient 
binding to COX-1 pocket is prevented (72). 
1.2.2.5. Structure Activity Relationships Studies of Non-Steroidal Anti-
Inflammatory Drugs 
 
Figure 1-18: General Structure of NSAIDs 
NSAIDs structurally constitute of an acidic moiety (carboxylic acid or enols) 
attached to a planar, aromatic group. This can be represented as given below 
(see Fig. 1): Due to above structural features, the NSAIDs are characterized 
by the following properties (73): 
1. Most of the NSAIDs are strong organic acids with pK as in the 3–5 range 
and are carboxylic acids. The acidic group is essential for COX inhibitory 
activity. 
2. The NSAIDs differ in their lipophilicities based on the lipophilic character 
of their aryl groups and additional lipophilic moieties and substituents. 
3. The acidic group in these compounds serves a major binding group (ionic 




4. The acidic group also serves as a major site of metabolism by conjugation. 
Thus a major pathway of clearance for many NSAIDs is glucuronidation 
1.2.2.6. Molecular Docking 
Molecular Docking Molecular docking is one of the most frequently used 
methods in Structure-Based Drug Design (SBDD) because of its ability to 
predict, with a substantial degree of accuracy, the conformation of small-
molecule ligands within the appropriate target binding site (Figure 2) (74).  
Following the development of the first algorithms in the 1980s, molecular 
docking became an essential tool in drug discovery (75). For example, 
investigations involving crucial molecular events, including ligand binding 
modes and the corresponding intermolecular interactions that stabilize the 
ligand-receptor complex, can be conveniently performed (76). Furthermore, 
molecular docking algorithms execute quantitative predictions of binding 
energetics, providing rankings of docked compounds based on the binding 
affinity of ligand-receptor complexes (75).  The identification of the most likely 
binding conformations requires two steps: (i) exploration of a large 
conformational space representing various potential binding modes; (ii) 
accurate prediction of the interaction energy associated with each of the 
predicted binding conformations (77). Molecular docking programs perform 
these tasks through a cyclical process, in which the ligand conformation is 
evaluated by specific scoring functions. This process is carried out recursively 





Figure 1-19: Outline of the molecular docking process.  (A) Three-
dimensional structure of the ligand; (B) Three-dimensional structure of 
the receptor; (C) The ligand is docked into the binding cavity of the 
receptor and the putative conformations are explored; (D) The most 
likely binding conformation and the corresponding intermolecular 
interactions are identified. The protein backbone is represented as a 
cartoon. The ligand (carbon in magenta) and active site residues (carbon 
in blue) are shown in stick representation. Water is shown as a white 
sphere and hydrogen bonds are indicated as dashed lines. 
1.2.2.7. Glucocorticoids 
Glucocorticoids (GCs) are steroidal hormones that are naturally produced by 
vertebrates and function to control inflammation (79), Because of their native 
role, synthetic GCs have been produced and used to treat a variety of 
inflammatory-related diseases including asthma (80). Inflammatory bowel 
disease (81).  Rheumatoid arthritis (82), and systemic lupus erythematous (83). 
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Both synthetic and natural GCs act by binding to and activating the 
glucocorticoid receptor (GR), a transcription factor that acts as an activator or 
repressor of several genes by direct binding with specific DNA sequences or 
by interfering with the transcriptional activity of other transcription factors 
(84). 
Several mechanisms have been proposed to explain the inhibitory effect of 
GCs on the transcription of inflammatory genes. Many of them are related to 
the inhibition of Nuclear Factor-κB (NFκB) activation at different levels, 
including a direct physical association of GR with NFκB and the induction of 
the expression of the regulatory protein IκBα (85). 
1.2.2.8. Immunomodulatory drugs 
Immunomodulatory drugs, such as thalidomide and its analogs, are also 
inhibitors of NFκB activation (86). These drugs have anticancer, anti-
inflammatory, and antiangiogenic actions by modulating the secretion of 
cytokines such as Tumor Necrosis Factor Alpha (TNF-α) and interleukins IL-
6 and IL-12 (87). It has been proposed that the anti-inflammatory effect of these 
drugs occurs by inhibition of IκB degradation and downregulation of NFκB 
DNA-binding activity. Inhibitors of TNF-α are also being used currently for 
the treatment of inflammatory diseases such as rheumatoid arthritis, Crohn's 
disease, and asthma (88). 
These molecules act by inhibiting the binding of TNF-α to its receptor or by 
neutralizing the soluble and the membrane-bound forms of TNF-α (89). 
However, several adverse effects for these drugs have been described, such as 




1.3. Literature Review  
In one study, A series of 3-(20-substituted indolidene aminothiazol-40-yl)-2-
(4-chlorophenyl) indoles (3ae3d), 3-(20-substituted indolidene aminooxazol-
40-yl)-2-(4-chlorophenyl) indoles (3a0e3d0) and 3-[20-(10-substituted 
phenyl-30-substituted indolyl formazan-40-yl) thiazol-40-yl]-2-(4 
chlorophenyl) indoles (4ae4h), 3-[20-(10-substituted phenyl-30-substituted 
indolyl formazan-40-yl) oxazol-40-yl]-2-(4-chlorophenyl) indoles (4a0e4h0) 
were synthesized and evaluated for their anti-inflammatory activity against 
carrageenan induced oedema in albino rats at a dose of 50 mg/kg p.o.  All the 
compounds of this series show moderate to good activity. The most active 
compound of this series 3-(20-methyl indolidene aminothiazol-40-yl)-2-(4-
chlorophenyl) indole (3b) is found to be the most potent and has shown higher 
percent of inhibition of oedema, lower ulcerogenic liability and acute toxicity 
than the reference drug phenyl butazone (91). 
In another study, synthesis and pharmacological screening of various 
derivatives of 3-(4, 5-dihydropyrazolyl)-indoles viz 2-(4-substitutedphenyl)-
3-(5-(4-substitutedphenyl)-1-phenyl-4, 5-dihydro-1H-pyrazol-3-yl)-1H-
indole (4a-4r) is reported. The compounds (4a-4r) were synthesized by 
cyclization of chalcones (3-(4-substitutedphenyl)-1-(2-(4-substitutedphenyl)-
1Hindol-3-yl) prop-2-en-1-one) of indole. All the compounds tested (4a-4r) 
showed inflammatory activities. Seven compounds (4d, e, h, j, k, p, q) out of 
18 compounds showed very good anti-inflammatory activity comparable to 
the standard drug indomethacin with very less ulcerogenic action. Compounds 
4j and 4k showed 86.38 and 88.31% inhibition in paw edema, 79.42 and 1.16 
and 1.13 of severity index respectively compared to 92.73 %, 78.46 % and 
2.16 values of indomethacin. The results showed that the incorporation of 
appropriately substituted pyrazoline ring in indole nucleus can afford good 
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analgesic and anti-inflammatory activities with reduced gastric irritation to 
the compounds (92). 
In 3th study, two novel series of oxadiazole and oxadiazoline analogs 
possessing an indole nucleus were synthesized for their potential anti-
inflammatory activity. Most of the test compounds demonstrated appreciable 
anti-inflammatory activities. The anti-inflammatory activity of oxadiazoles at 
doses of 100 mg/kg was shown by their ability to provide 27–66%, 14–32%, 
and 20-51% protection against carrageenan-induced rat paw edema, moist 
cotton pellet-induced, and dry cotton pellet-induced granuloma, respectively. 
On the other hand, the anti-inflammatory properties of oxadiazolines at doses 
of 100 mg/kg were reflected by their ability to provide 20-56%, 11–26%, and 
25–47% protection against carrageenan-induced rat paw edema, moist cotton 
pellet-induced, and dry cotton pellet-induced granuloma, respectively. The 
ulcerogenic potential of the compounds was determined (93). 
In 4th study, some new Synthesis of (N-carbamimidoyl 1-4-(2-oxo-1 
(piperidine-1-ylmethyl) indolin-3-ylidineamino) benzene sulphonamide) has 
been synthesized from isatin & different p-substitute aniline. All the 
synthesized isatin derivatives have been investigated for their anti-
inflammatory activity (94). 
In the 5th study a series of 2-thienyl-3-substitued indole derivatives (1-11) 
were synthesized. All the synthesized compounds have been tested for their 
anti-inflammatory activity. Twelve of the prepared compounds 50 were 
evaluated for their anti-inflammatory activity (against carrageenan induced 
oedema in albino rats at a dose of 50 mg/kg body weight using indomethacin 
at a dose of .25mg/kg body weight as a standard drug) and ulcerogenic effect 
compound 9a exhibited 55.31% inhibition with ulcerogenic activity less than 
that of indomethacin (95). 
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In 6rd study, in a new group of 3-methyl-2-phenyl-1-substituted-indole 
derivatives (10a–f), the indomethacin analogs. All the synthesized compounds 
were evaluated for their anti-inflammatory (in vitro and in vivo) and analgesic 
activities. The methanesulphonyl derivatives 10d, e and f showed the highest 
anti-inflammatory (in vitro and in vivo). In addition, molecular docking 
studies were performed on compounds 10a–f and the results were in 
agreement with that obtained from the in vitro COX inhibition assays (96). 
In 7th study, design and synthesis of novel oxadiazolyl-2-oxoindolinylidene 
propane hydrazides as amide tethered hybrids of indole and oxadiazole and 
their evaluation for anti-inflammatory and analgesic activity. The final 
derivatives 3-[5-(4-hydroxyphenyl)-1,3,4-oxadiazol-2-yl]-N’-[2-oxo-1,2-
dihydro-3H-indol-3-ylidene]propane hydrazide and 3-[5-(4-methylphenyl)-
1,3,4-oxadiazol-2-yl]-N’-[2-oxo-1,2-dihydro-3H-indol-3-ylidene]propane 
hydrazide were found to be highly promising molecules with severity index 
of 0.35 and 0.56, respectively, which is promising for an analgesic compound. 
The hydroxy and methyl substitution on phenyl ring system provided with 
active anti-inflammatory compounds having increase in reaction time of 84.11 
and 83.17%, respectively compared to standard drug at 85.84%. Molecular 
docking studies exhibit comparable interaction with synthesized derivatives 
and standard drug having a dock score of −4.44 by the K-nearest neighbour 
genetic algorithm method (97). 
In 8th study, a novel synthesis of 2-hydroxy-N�-(2-oxoindolin-3-ylidene) 
benzohydrazide derivatives, the compounds were screened for in vivo anti-
inflammatory activity by carrageenan induced paw edema method. The tested 
compounds have shown mild-to-moderate anti-inflammatory activity. The 
compounds VIIc and VIId exhibited 65%and 63%of paw edema reduction, 
respectively. The molecular docking studies were also carried out into the 
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active site of COX- 1 and COX-2 enzymes (PDB ID: 3N8Y, 3LN1, resp.) 
using VLife MDS 4.3. The compounds VIIc, VIId, and VIIf exhibited good 
docking scores of −57.27, −62.02, and −58.18 onto the active site of COX-2 
and least dock scores of −8.03, −9.17, and −8.94 on COX-1 enzymes and were 
comparable with standard COX-2 inhibitor celecoxib. A significant 
correlation was observed between the in silico and the in vivo studies. The 
anti-inflammatory and docking results highlight the fact that the synthesized 
compounds VIIc, VIId, and VIIf could be considered as possible hit as 
therapeutic agents (98). 
In 9th study, a series of new indole-hydrazone derivatives were synthesized. 
All synthesized compounds were screened for their anti-inflammatory against 
carrageenan induced oedema in albino rats at a dose of 0.2 mmol/kg using 
indomethacin as a standard drug. The reduction in oedema formation was 
ranged between 72.3 – 89.3 % for all the synthesized compounds compared 
to indomethacin (46 % inhibition). Furthermore, all molecules were docked 
to the active site of both cox-1 and cox-2 using the docking program Molego 
virtual docker. All prepared compounds showed high docking score against 
both cox-1 and cox-2. The dock scores and binding energy were found to be 
in good agreement with the pharmacological results. Finally, the drug likeness 
and bioactivity were predicted using Molinspiration software. The results 
revealed that all new compounds show good drug likeness score and 
bioactivity score (99). 
In the 10th study a series of bioactive bis(indolyl)methanes , anti-inflammatory 
activity of the synthesized bis(indolyl)methanes are evaluated in vitro and 
compared to standard drug diclofenac. The majority of the compounds 
showed good anti-inflammatory activity interestingly, compounds 3j, 3i, 3k 
and 3g exhibited much higher anti-inflammatory activity than the standard 
29 
 
diclofenac drug and thus qualify for clinical trials to be used as an anti-
inflammatory compounds (100). 
In 11th study, a series of fused pyrroles were synthesized and tested for their 
in vivo anti-inflammatory activity. Among 14 examined derivatives, 5 
derivatives (1b–e, g and 5b), showed a promising anti-inflammatory activity 
equivalent to reference anti-inflammatory drugs (indomethacin and 
ibuprofen). A molecular docking study was conducted to interpret the 
biological activities of the tested compounds. The docking results were 
complementary with the phase of the biological survey and confirmed the 
biological effects (101). 
In 12th study, a new group of (4-substitutedphenyl)(3-((2-(4- 
substitutedphenyl)hydrazono)methyl)-1H-indol-1-yl)methanone derivatives 
13a-f as indomethacin analogs. All the synthesized compounds were 
evaluated in vitro for COX-1/COX-2 inhibitory activity and in vivo for their 
anti-inflammatory activity in comparison with the parent drug indomethacin. 
Compounds 13a,b,d,e which contain SO2Me or SO2NH2 group as a 
pharmacophore of COX-2, exhibited the most anti-inflammatory and 
selectivity actives so, they were more evaluated by calculating their ED50% 
doses and ulcerogenic indices to ensure their gastric safety margin relative to 
indomethacin (102). 
In 13th study, a new series of 2-(5-methoxy-2-methyl-1H-indol-3-yl)-N0-[(E)-
(substituted phenyl) methylidene] acetohydrazide derivatives (S1–S18) were 
synthesized and evaluated for their anti-inflammatory activity, analgesic 
activity, ulcerogenic activity, lipid peroxidation, ulcer index and 
cyclooxygenase expression activities. Three synthesized compounds (S3, S7 
and S14) have shown significant anti-inflammatory activity as compared to 
the reference drug indomethacin. Compound S3 was further tested for 
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ulcerogenic index and cyclooxygenase (COX) expression activity. It was 
selectively inhibiting COX-2 expression and providing the gastric sparing 
activity. Docking studies have revealed the potential of these compounds to 
bind with COX-2 enzyme. Compound S3 formed a hydrogen bond between 
OH of Tyr 355 and NH2 of Arg 120 with carbonyl group and this hydrogen 
bond was similar to that formed by indomethacin. This study provides insight 
for compound S3, as a new lead compound as anti-inflammatory agent and 
selective COX-2 inhibitor (103). 
In 14th study, substituted indoline-based dihydroxy-carbamides (5a–i) were 
synthesized and evaluated as the cyclooxygenase-2 (COX-2) inhibitors to 
testify their inflammatory regulations through COX-2 inhibition. Enzyme-
linked immunosorbent assay-based competitive (COX-2) inhibition (in vitro) 
followed by a molecular docking study (in silico) was executed to ensure the 
mode of interaction between 5a–i and COX-2. Apart from COX-2 inhibition 
studies, free-radical scavenging ability (H2O2 estimation method) and the 
human red blood cell membrane protection (in vitro anti-inflammatory) 
capability of the compounds 5a–i assessment were also evaluated. Excellent 
antimicrobial and anticancer activity exhibited by thiocarbamide substituted 
compounds (5a–d) than carbamide (5e–i). In molecular docking studies, the 
obtained binding affinity values of 5a–i indicated the therapeutic selectivity 
on COX-2 (PDB ID: 1CX2) over COX-1 (PDB ID: 1EQG). Established 
inhibitory constant (ki) values were found as low as in nanomolar/picomolar 
against COX-2. Reliable COX-2 inhibition of 78–92% and IC50 0.002–1.28 
μM were obtained. Human red blood cell membrane was found to be 
effectively stabilized/protected by 5a–i up to 98%. Excellent structure–
activity relationship predictions confirmed the drug ability potentials of 5a–i 
as effective, future anti-inflammatory drugs (104). 
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In 15th study, a novel N-acyl substituted indole-linked benzimidazoles and 
naphthoimidazoles were synthesized. Anti-inflammatory activity for all target 
compounds was evaluated in-vitro. The synthesized compounds hinder the 
biofilm formation and control the growth of the pathogen, Staphylococcus 
epidermis. Anti-microbial activity of the compounds was evaluated against 
both Gram negative and Gram positive bacteria such as Staphylococcus 
aureus (MTCC 2940), Pseudomonas aeruginosa (MTCC424), Escherchia coli 
(MTCC 443) and Enterococcus fecalis (105). 
In 16th study, new indole derivatives 4a–h and 5a–c, which were synthesized 
via Fisher indole reaction, evaluated for both their in vivo anti-inflammatory 
activities using rat paw edema method and their in vitro cyclooxygenase 
inhibitory activities. Then ulcerogenic liability, physicochemical parameters 
and molecular docking modelling were performed for the most potent ones. 
Promising results were obtained, where compound 4f was the best anti-
inflammatory agent and preferential COX-2/COX-1 inhibitor (90.5% edema 
inhibition, selective index = 65.71, ulcer index = 7.3), if compared with 
indomethacin (86.7% edema inhibition, selective index = 0.079, ulcer index 
= 20.20) (106). 
In 17th study, a series of 2-(4-(methylsulfonyl)phenyl)-1-substituted-indole 
derivatives 4a–f was designed and synthesized as indomethacin analogs; All 
synthesized compounds were assessed for their in vitro COX-2 inhibition 
effect as well as in vivo anti-inflammatory activity using indomethacin as a 
reference drug. All synthesized compounds showed good anti-inflammatory 
activity and more selectivity for COX-2 inhibition. A molecular modeling 
study was carried out and the results were compatible with that derived from 
in vitro COX-2 inhibition assays (107). 
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In the 18th study a set of two series having 42 compounds of 1, 2, 3-Tethered 
Indole-3-glyoxamide derivatives were synthesized and were also evaluated 
for their in vitro cyclooxygenase-1 (COX-1), cyclooxygenase-2 (COX-2), 5-
lipoxygenase (5-LOX) inhibitory activities with in vivo anti-inflammatory. 
Results from carrageenan-induced hind paw edema demonstrated that 
compounds 11b, 11l, 11q and 13q exhibited significant anti-inflammatory 
activity with 69–77% inhibition at 3 h, 75–82% inhibition at 5 h when 
compared to the standard drug indomethacin (66.6% at 3 h and 77.94% at 5 h). 
Ulcerogenic study revealed that compounds 11q and 13q did not cause any 
gastric ulceration. In silico molecular docking studies demonstrated that 
compound 11q illustrated very good binding affinities towards COX-2 and 5-
LOX (108). 
In the 19th study the objective of this work was to obtain and evaluate anti-
inflammatory in vitro, in vivo and in silico potential of novel indole-N-
acylhydrazone derivatives. In total, 10 new compounds (3a–j) were 
synthesized in satisfactory yields, the results for COX inhibition assays 
showed that compound 3b is a selective COX-2 inhibitor, but with less 
potency when compared to celecoxib, and compound 3a not presented 
selectivity towards COX-2. The molecular docking results suggest 
compounds 3a and 3b interact with the active site of COX-2 in similar 
conformations. In vivo carrageenan-induced paw edema assays were adopted 
for the confirmation of the anti-inflammatory activity. Compound 3b showed 
better results in suppressing edema at all tested concentrations and was able 
to induce an edema inhibition of 100% after 5 h of carrageenan injection at 
the 30 mg /kg dosage, (109) 
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1.4.  Rationale of the study   
A large number of studies  have used the indole ring based NSAIDs as in 
Indomethacin , as a target to improve their COX-2 selectivity and reduce their 
ulcerogenic side effects attributed to their high COX-1 selectivity and the 
acidic properties of the drug. Also, in recent studies, novel series of 
indomethacin analogs were synthesized which were approved as good COX-
2 selective inhibitors. So, these results encouraged us to continue the research 
on such type of compounds. However, the recent market removal of some 
selective COX2 inhibitors such as rofecoxib and valdecoxib due to their 
adverse cardiovascular side effects clearly encourages the researchers to 
explore and evaluate alternative templates with COX-2 inhibitory activity Our 
strategy in this research is based on maintaining the potency of the 
indomethacin by keeping the main scaffold of the drug with trials to increase 
COX-2 selectivity via the modifications of the side groups  
Previous studies revealed that, indole derivatives have anti-inflammatory 
activity so in this study novel indole derivatives compound was synthesized  
based on molecular hybridization approach between the known anti-
inflammatory drug indomethacin and indole ring in an attempt to obtain a 
compound with anti-inflammatory activity with reduced GI toxicity, since 
previous studies revealed that modification of carboxylic acid group of 
existing NSAIDs will reduce toxicity and enhance selectivity toward COX 2. 
1.5.  Objectives of the Study   
1.5.1. General Objectives 
To assess anti-inflammatory activity on acute and sub-acute inflammation of 
most promising compound of a synthetic novel indole derivative and 
elucidating of mechanisms of action. 
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1.5.2. Specific Objectives 
1- To recognize the hypothetical binding site for the four compounds with the 
cyclooxygenase-2 employing Molecular Operating Environment (MOE) 
software and select the most promising compound, in silico  
2- To evaluate the anti-inflammatory activity of the m1k on acute 
inflammatory phase using paw edema model, in vivo. 
3-To assess anti-inflammatory activity of the m1k on sub-acute phase using 
granuloma test model, in vivo. 
4-To elucidate mechanism of action of the m1k using RBCs membrane 
stabilizing activity assay, in vitro. 
5- To determine acute ulcergencitiy of m1k and compare it with standard 












2. Materials and Methods  
2.1. Materials  
Table 2-1:  Chemicals with their Suppliers. 
Number  Item Source  




Oxford laboratory reagent (Mumbai - 
India) 
3 Carrageenan Oxford laboratory reagent (Mumbai - 
India) 
4 Sodium chloride  AIN SUDAN Pvt. Ltd. Co.  (Sudan) 
 
2.2. Instruments 
Table 2-2:  Instruments Used in the Experiments 
Number  Item  Source  
1 T60UV-Spectrophotometer  PG-INSTRUMENTS  
2 Benchtop centrifuges  Centurion scientific (UK) 
3 Water bath  Seott Science UK (UK) 




2.3. Experimental animals  
Healthy adult wistar strain of albino rats , two to three month old and weighing 
150 - 200 g , were obtained from National Research Centre , kept and 
maintained under standard laboratory conditions (temperature, 25 ± 2 ˚C; 
humidity, 60 % ± 5 ˚C and 12 h light: 12 h dark cycle). The animals were feed 
with standard laboratory diet and allowed to drink water freshly free. 
2.4. The tested substances 
The whole tested substances used throughout the study were synthesized by 
Dr. Tilal Alsaman Elemam Elbashir, Department of pharmaceutical 
chemistry, Omdurman Islamic University. 
 




                           M3K                                                                                   M4k 
Figure 2-1: chemical structures of tested substances  
2.5.  Experimental Designs  
2.5.1. Molecular Docking Study    
This comparative docking study was performed by docking our compounds 
m1k, m2k, m3k and m4k into the COX-2: and compared with the parent co-
crystallized ligands. The main purpose of this study was to predict the binding 
mode and the binding affinity of the newly synthesized compounds with 
relevant amino acids in the binding sites of COX-2 enzyme. Molecular 
modelling investigations were carried out using HP laptop  running Intel ® 
Core ™  i3 Processor, 2 GB RAM, 300 GB hard disk, and Intel 2 GB graphics 
card. Molecular Operating Environment (Moe 2008) module was employed 
for the docking studies. Docking for the synthesized compounds (m1k, m2k, 
m3k and m4k) and reference compound indomethacin were performed via 
their 3D structures and energy was minimized using MMFF94x of Molecular 
Operating Environment energy minimization module (MOE, Version 2008, 
Chemical Computing Group Inc., Montreal, Quebec, Canada).3D crystal 
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structure of COX-2 enzyme (PDB ID: 4COX) was selected from Protein Data 
Bank database (http://www.rcsb.org). The reported protocol was followed for 
preparing selected 3D structure of COX-2 enzyme for docking. Docking 
procedure was also followed using the standard protocol implemented in 
MOE 2008 and the geometry of resulting complexes was studied using the 
MOE’s Pose Viewer utility (103). See table 3.1. 
2.5.2. Assessment of Anti-inflammatory Activity Using Carrageenan-
Induced Rat Paw Edema (Acute Model), in vivo study 
Anti-inflammatory activity was evaluated using carrageenan-induced rat paw 
edema (110). Wistar albino rats (150 - 200 g) were divided into groups of six 
animals each. The first group served as the control at dose 10ml/kg, the 
second, third received m1k at two doses of 33.3 and 66.6 mg/kg respectively, 
and fourth group received indomethacin at dose10 mg/kg, administration of 
m1k and indomethacin were administered intra-peritoneal (i.p), then after 1 h 
carrageenan solution (0.1 ml of 1% carrageenan solution) was injected into 
the sub plantar region of the right hind paw of the rats. The paw thickness was 
measured at 1, 2 and 3 h using a micrometer screw gauge (111). 




 × 100                                      
Where 𝑇˳ = Initial paw thickness of the rat before the administration of 
carrageenan (at 0 time).  𝑇𝑡 = Final paw thickness of the rat after the 
administration of carrageenan (at 3 hour time interval)  
2.5.3. Assessment of Anti-inflammatory Activity Using Cotton pellet-
Induced Granuloma (Sub-acute Model), in vivo study  
Sterilized cotton pellets weighing 10 mg ± 1 were implanted subcutaneously 
into both sides of the groin region of each rat. The animals were divided into 
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three groups containing six animals in each group. Group I served as control 
group and received DMSO daily at a dose of 1 ml/150 g body weight i.p., 
group II received 10 mg/kg, intra-peritoneal (i.p).  Indomethacin (standard 
drug) and groups III, received the M1k at dose of 66.6 mg/kg, i.p., 
respectively, daily for seven consecutive days. On the 8th day, the animals 
were killed and the pellets together with the granuloma tissues were carefully 
removed, dried in an oven at 60°C, weighed and compared with control  (112). 
Percentage inhibition of granuloma  
=
 𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑝𝑒𝑙𝑙𝑒𝑡 (𝑐𝑜𝑛𝑡𝑟𝑜𝑙) − 𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑝𝑒𝑙𝑙𝑒𝑡(𝑡𝑟𝑒𝑎𝑡𝑒𝑑) 
 𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑝𝑒𝑙𝑙𝑒𝑡 (𝑐𝑜𝑛𝑡𝑟𝑜𝑙)
 × 100  
 
2.5.4. Assessment of Anti-inflammatory Activity Using Membrane 
Stabilizing Activity Assay, in vitro study 
The reaction mixture (2ml) consisted of 1 ml of M1k different concentrations 
(100,200,300 and 500 μg/ml) and 1 ml of 10% human red blood cells 
(HRBCs) suspension, instead of test sample only saline was added to the 
control test tube. Indomethacin was used as a standard drug. All the centrifuge 
tubes containing reaction mixture were incubated at 56 ºC for 30min. At the 
end of the incubation the tubes were cooled under running tap water. The 
reaction mixture was centrifuged at 2500 rpm for 5 min and the absorbance 
of the supernatants was taken at 560 nm. The experiment was performed in 
triplicates for all the test samples. The percentage inhibition of haemolysis 
was calculated as follows (113): 
 % Membrane stabilization  =
 𝐴𝑐−𝐴𝑡 
𝐴𝑐
 × 100                                         
Where, Ac is the absorbance of control, At is the absorbance of test sample. 
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2.5.5. Acute Ulcerogenesis, in vivo study 
Albino rats have been divided into different groups consisting of six animals 
in each group. Ulcerogenic activity was evaluated after p.o. (per oral) 
administration of M1K at the dose 66.66 mg/kg and indomethacin at the dose 
of 10 mg/kg. Control rats received p.o. (per oral) administration of vehicle 
(1ml of DMSO). Food but not water was removed 24 h before administration 
of the test compounds. After the drug treatment, the rats were fed normal diet 
for 17 h and then sacrificed. The stomach was removed and opened along the 
greater curvature, washed with distilled water and cleaned gently by dipping 
in saline. The mucosal damage was examined by means of a magnifying glass. 
For each stomach, the mucosal damage was assessed according to the 
following scoring system (114): 
Table 2-3: Lesion Specifications of Gastric Ulcer and it Scale  
Scale  Lesion Specification’s 
0  Normal (No injury) 
1 Latent small red spot 
2 Wide red spot 
3 Slight injury 
4 Severe injury 
 
The following parameters were calculated (102): 
1- % Incidence /10 = [Number of rats showing ulcer of any grade divided by 
total number of rats in the group x 100]/10.  
2- Average number of ulcer = Number of ulcer in the group/ total number of 
rats in the group. 
3- Average severity =Σ [each ulcer multiplied by its score of severity/ number 
of ulcer in the group. 
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4- Ulcer index = the sum of the above three parameters. (% Incidence /10 + 
Average number of ulcer + Average severity). Ulcer index value was 
compared to that of indomethacin.  
2.6. Statistical analysis 
Statistics was expressed as a mean ± standard error of mean and statistical 
analysis was carried out by one‑way ANOVA with Tukey’s test performed 
using GraphPad InStat version 7.00, GraphPad Software, San Diego, 
California, USA, www.graphpad.com. P value was considered statistically 
significant when P < 0.05. 
2.7. Ethical Considerations  
All the studies and experimental protocols were approved by the 
Institutional Animal Ethical Committee (I.A.E.C) in the department of 
pharmacology, Faculty of pharmacy, International University of Africa, 



























3.1.  Molecular docking results of the indomethacin and M1k, M2k, 
M3k and M4k with COX 2 enzyme 
Table 3-1: Molecular docking results of the indomethacin and 
indomethacin derivatives with COX 2 enzyme 







In molecular docking of four new synthetic indole derivatives and 
indomethacin with COX 2 enzyme, the m1k showed greater Affinity energy 
towards COX 2 enzyme (-14.56 kcal/mol), the m2k and indomethacin showed 
moderate Affinity energy towards COX 2 enzyme (-12.88 and-13.06 kcal/mol 
respectively), while m3k and m4k showed mild Affinity energy towards COX 
2 enzyme (-12.50 and -13.54 kcal/mol respectively). 
M1k was selected to pharmacological experiments because of economic 




3.2.  Effect of indomethacin and m1k on carrageenan induced rat paw 
edema. 




Values expressed as mean ± SEM (n = 6) *P < 0.05, **P < 0.01, ***P < 0.001 
as compared to control group. 
At 1st , 2nd  and 3th  hour, M1k at dose 33.33 mg/kg showed significant effect 
on reducing paw edema (P < 0.001, P < 0.05 and **P < 0.01 respectively), 
and M1k dose 66.66 mg/kg showed significant effect on reducing paw edema 
























2 Indomethacin 10  




























ml/kg   
4.75± 0.03***        
ns 
4.73± 0.17 **   
 ns  





10 mg/kg showed significant effect on reducing pow edema (P < 0.001, P < 
0.01and P < 0.001 respectively), compared to control. 
At 1st , 2nd  and 3th  hour, M1k at dose 33.33 mg/kg  and dose 66.66mg/kg 




















                   After 1 hour                                     after 2 hour      
   
After 3 hour  
 
Figure 3.1: effect of control, indomethacin and m1k on carrageenan 
induced rat paw edema during time interval every 1 hour.  
Values expressed as mean ± SEM (n = 6) *P < 0.05, **P < 0.01, ***P < 0.001 
**** P < 0.0001 as compared to control group. 
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3.3. Anti-inflammatory activity of indomethacin and m1k on 
carrageenan-induced rat paw edema. 
Table 3-3: Anti-inflammatory activity of indomethacin and m1k on 
carrageenan-induced rat paw edema.                                                 
 
Values expressed as mean ± SEM (n = 6) *P < 0.05, **P < 0.01, ***P < 0.001 
as compared to indomethacin group. 
At 1st , 2nd  and 3th  hour, M1k at dose 33.33 mg/kg showed low percentage 
inhibition paw edema (58.9 %, 63.3 % and 73.3 % respectively), and M1k 
dose 66.66 mg/kg showed moderate percentage inhibition paw edema (61.7 
%, 68 % and 77.2 % respectively) compared with indomethacin at dose 10 
mg/kg which showed (74%, 82,5% and 86.8 % respectively) 
At 1st , 2nd  and 3th  hour, M1k at dose 33.33 mg/kg  and 66.66 mg/kg showed 









paw edema   




 paw edema     




edema   at 3th  
hour 
(X±SEM) 








33.33  58.9± 3.93*  63.3±0.49** 73.3±2.84** 








Figure 3-2: Anti-inflammatory activity of indomethacin and m1k on 
carrageenan-induced rat paw edema 
Values expressed as mean ± SEM (n = 6) *P < 0.05, **P < 0.01, ***P < 0.001 










3.4. Effect of indomethacin and m1k on cotton pellet-induced 
granuloma. 
Table 3-4: Effect of indomethacin and m1k on cotton pellet-induced 
granuloma. 
 
Values expressed as mean ± SEM (n = 6) *P < 0.05, **P < 0.01, ***P < 0.001 
as compared to control group. 
M1k at dose 66.66 mg/kg showed greater significant effect (p< 0.001) on 
cotton pellet-induced granuloma while indomethacin at dose 10 mg/kg 







Group number  Groups treatment Dose  Mean dry 
granulation 
tissue in mg 
 (Mean ± SEM) 
1 Control 
 
10 ml /kg 
 
45.3 ± 4.81 
 
 
2 Indomethacin 10 mg/kg 
 
31 ± 3.75* 
 








Figure 3-3: Effect of control, indomethacin and m1k on cotton pellet-
induced granuloma. 
Values expressed as mean ± SEM (n = 6) *P < 0.05, **P < 0.01, ***P < 0.001 








3.5. Anti-inflammatory activity of indomethacin and m1k on Cotton 
pellet-induced granuloma. 
Table 3-5: Anti-inflammatory activity of indomethacin and m1k on 
Cotton pellet-induced granuloma. 
 
Values expressed as mean ± SEM (n = 6) *P < 0.05, **P < 0.01, ***P < 0.001 
as compared to indomethacin group. 
The m1k at dose 66.66 mg/kg showed the greater inhibition percentage of 
granuloma tissue formation 60.93% (P < 0.001) compared with indomethacin 










  Group  
     number 
Group treatment  Dose  
( mg/kg) 
         
   Percentage inhibition  
   of granuloma tissue 
   formation 
    (Mean ±SEM) 
1 Indomethacin 10 
    
  30.66 ± 5.22 





Figure 3-4: Anti-inflammatory activity of indomethacin and m1k on 
cotton pellet-induced granuloma. 
 
Values expressed as mean ± SEM (n = 6) *P < 0.05, **P < 0.01, ***P < 
0.001 as compared to indomethacin group. 
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3.6. Effect of indomethacin and m1k on membrane stabilizing activity 
assay. 
Table 3-6: Effect of indomethacin and m1k on membrane stabilizing 
activity assay. 
Values expressed as mean ± SEM (n = 6) *P < 0.05, **P < 0.01, ***P < 
0.001as compared to control group. 
M1k at doses 100, 200, 300 and 500 μg//ml showed greater significant  
effects on membrane stabilizing activity assay (P < 0.001, P < 0.001, P < 
0.001 and P < 0.001 respectively), while indomethacin at dose 100 μg//ml 
showed greater significant effect (P < 0.001) compared with control. 
 
Treatment (s) Concentrations 
(μg//ml) 
Absorbance at 660nm (Mean 
±SEM) 
Control 1ml 0.082± 0.001155 
Indomethacin  100 0.0041±  0.000173*** 
M1k  100 0.0011±  0.0001*** 
M1k 200 0.0012 ±  0.000115*** 
M1k 300 0.00127± 0.00012*** 




Figure 3-5:  Effect of indomethacin and m1k by membrane stabilizing 
activity assay. 
Values expressed as mean ± SEM (n = 6) *P < 0.05, **P < 0.01, ***P < 






3.7. Anti-inflammatory activity indomethacin and m1k on membrane 
stabilizing activity assay. 
Table 3-7: Anti-inflammatory activity indomethacin and m1k on 
membrane stabilizing activity assay. 
Values expressed as mean ± SEM (n = 6) *P < 0.05, **P < 0.01, ***P < 0.001 
**** P < 0.0001 as compared to indomethacin group. 
M1k at doses 100, 200, 300 and 500 μg//ml showed greater percentage 
inhibition of haemolysis (98.66, 98.53, 98.45 and 97.35 % respectively) 
compared to indomethacin at dose 100 μg//ml (94.99 %).                                                            
M1k at dose 500 μg/ml the percentage inhibition of haemolysis was decreased 






Group number Treatment (s) Concentrations  
( μg//ml) 
% Inhibition of 
haemolysis 
(X±SEM) 
1 Indomethacin 100 94.99 ±0.2562 
2 M1k 100 98.66±0.1054*** 
3 M1k 200 98.53±0.1588*** 
4 M1k 300 98.45±0.165 *** 




Figure 3-6: Anti-inflammatory activity indomethacin and m1k on 
membrane stabilizing activity assay. 
Values expressed as mean ± SEM (n = 6) *P < 0.05, **P < 0.01 ***P < 








3.8. Ulcer index of m1k in comparison with indomethacin as a 
reference drug. 







 incidence  
Average 
 number of 
 ulcer 
Average 
 severity  
Ulcer  
index 
Indomethacin  10  5 1.66 2 7.99 ±0.333 
M1k 66.66 10 1 4 15 ±0 **** 
 
Values expressed as mean ± SEM (n = 6) *P < 0.05, **P < 0.01 and ***P < 
0.001, as compared to indomethacin group. 
The m1k at dose 66.66 mg/kg were tested for their ulcerogenic liability in 
comparison with indomethacin at dose 10 mg/kg (Table 3.8), the m1k showed 
higher incidence percentage of ulcer (% incidence= 10), compared to  
indomethacin showed lower incidence percentage of ulcer (% incidence=5).  
The m1k showed lower average number of ulcer per rat (=1) while 
indomethacin showed higher average number of ulcer per rat (=1.66) 
The m1k showed greater average severity (average severity =4), while 
indomethacin lower average severity (average severity=2) 
The results revealed that, the m1k exhibited greater ulcerogenic liability 









Figure 3-7: Ulcer index estimation 
Values expressed as mean ± SEM (n = 6) *P < 0.05, **P < 0.01, ***P < 0.001, 





















 For new four synthetic indole derivatives were designed, synthesized 
chemically and characterized using various spectral techniques to act as COX-
2-selective inhibitor NSAIDs, according to my knowledge no 
pharmacological studies were done neither clinical nor pre-clinical. 
1- 4.1. Docking results of the indomethacin and indole derivatives with 
COX-2 enzyme. 
Four new indole derivatives compounds and indomethacin were docked with 
COX 2 enzyme to select most promising compound compared with 
indomethacin, and to charity the possible mechanism of action. Indomethacin 
showed relatively higher affinity to COX 2 (Affinity energy =-13.06 
kcal/mol), m1k showed the highest affinity to COX 2 (Affinity energy =-
14.56 kcal/mol), and m4k showed higher affinity to COX 2 (Affinity energy 
=-13.54 kcal/mol) (See table: 3-1). From this findings m1k was selected to 
pharmacological experiments.  
 No published papers similar to this indole derivative (m1k), so other relative   
indole derivative papers the results of which were used to compare with this 
study findings. 
Fatahala SS et, al (101) 2017 study indole derivatives compounds and 
indomethacin docked with COX 2 enzyme, 5b and 1b showed moderate  
affinity to COX 2 (Affinity energy = -10.38 kcal/mol and -11.68 kcal/mol) 




The m1k, m4k, m2k and m3k showed relatively moderate affinity to COX 2 
(Affinity energy = (-14.56 kcal/mol, -13.54 kcal/mol, -12.88 kcal/mol and -
12.5 kcal/mol respectively) compared with 5b and 1b (Affinity energy = -
10.38 kcal/mol and -11.68 kcal/mol respectively), there is significant 
difference between this study findings and Fatahala SS et, al 2017 study, may 
be due to the m1k, m4k, m2k and m3k binding with COX 2 by strong bond 
type.  
Bhat M, et, al (103) 2018 study indole derivatives compounds and indomethacin 
docked with cox2 enzyme, S1, S2 and S3 showed moderate relatively affinity 
to COX 2 (Affinity energy= -7.12 kcal/mol, -7.73 kcal/mol and -7.80 kcal/mol 
respectively respectively). 
The m1k, m4k, m2k and m3k showed moderate relatively affinity to COX 2 
(Affinity energy) compared with S1, S2, and S3, there is significant difference 
between this study findings and Bhat M, et, al 2018, may be due to the m1k, 
m4k, m2k and m3k binding with COX 2 by strong bond type. 
2- 4.2. Carrageenan-Induced Rat Paw Edema (Acute Model), in vivo 
study. 
The effect of m1k and indomethacin were evaluated using carrageen-induced 
rat paw edema test in comparison control, the m1k showed reduction in paw 
edema against carrageenan the highest significant effect (P value ***P < 
0.001) at the first and third hour after injection of carrageenan. The 
indomethacin showed reduction in paw edema against carrageenan, the 
highest significant effect of indomethacin (P value ***P < 0.001) at the first 
and third hour after injection of carrageenan (See table: 3-2). 
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The percentage of inhibition of paw edema of the m1k was evaluated using 
carrageen-induced rat paw edema test in comparison to indomethacin, the 
m1k showed the maximum percentage of inhibition at third hour (77.2% P 
value < 0.05) and minmum percentage of inhibition at first hour (58.9% P 
value < 0.05).While indomethacin showed the maximum percentage of 
inhibition at third hour (86.8%) and minmum percentage of inhibition at first 
hour (74%) (See table: 3-3). 
In Abdellatif KRA et.al(102) 2017 study the anti-inflammatory activity of the 
indole derivatives compounds compared to indomethacin was tested using the 
carrageen-induced rat paw edema test, Results indicated that after 1 h ,10f 10d 
and 10e showed relatively moderate percentage of anti-inflammatory activity 
(67.9%, 73.1% and73.5%  respectively),while indomethacin showed 
moderate percentage of anti-inflammatory activity (71.2%). Then after 3 h 
showed 10f, 10e and 10d showed good moderate of anti-inflammatory activity    
(66.8%, 71.8% and 80.1% respectively), compared to indomethacin (86.3%)  
The m1k and the 10f 10d and 10e showed there is may no significant 
difference between this study findings and Abdellatif KR et.al, 2016 study 
findings. 
In Chavan RS, et.al (92) 2010 study the anti-inflammatory activity of the indole 
derivatives compounds compared to indomethacin was tested using the 
carrageen-induced rat paw edema test, 4h and 4p after 2 h and 3h showed 
good percentage of anti-inflammatory activity (65.52%, and 69.28% 
respectively), 4H and 4P after 3h showed moderate percentage of anti-




The m1k and 4H and 4p showed there is may no significant difference 
between this study findings and Chavan RS, et.al, 2010 study findings. 
Carrageenan is biphasic; the early phase, observed about 1 h after carrageenan 
injection, is related to the production of serotonin, kinins and histamine, while 
the late phase is more controversial and complex, and has been attributed in 
part to kinins, prostaglandins, neutrophils infiltration, and lipoxygenase 
products of arachidonic acid metabolites(2). 
Suppression of the early phase may be associated with the inhibition of the 
release of early mediators, such as serotonin and histamine, whereas 
suppression of the second phase may be attributed to the inhibition of 
cyclooxygenase activity (3). 
3- 4.3. Cotton pellet-Induced Granuloma (Sub-acute Model), in vivo 
study. 
In order to assess its efficacy against proliferative phase of inflammation we 
have selected cotton pellet-induced granuloma in which tissue degeneration 
and fibrosis occurs. M1k showed greater significant effect (𝑃 < 0.001) on 
reduced the granuloma formation while indomethacin showed moderate 
significant effect (P< 0.05) compared to control (See table: 3-4). The m1k 
showed the greater inhibition percentage of granuloma tissue formation 
(60.93%) compared with indomethacin (30.66 %) (See table: 3-5).  
In Prasad BD et.al (94) 2012 the study assess the efficacy of indole derivatives 
against sub-chronic inflammation, the cotton pellet granuloma model in rats 
employed compounds SKb and SKe showed both mild significant effect (𝑃 < 
0.05) on reducing the granuloma formation while indomethacin mild 
significant effect (P< 0.05) compared to control. The SKb and SKe showed 
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mild inhibition percentage of granuloma tissue formation as (62.24% and 
65.91% respectively) compared with indomethacin (67.44 %). 
The m1k and the SKb and SKe showed there is may no significant difference 
between this study findings and that findings showed In Prasad BD et.al, 2012 
study findings. 
Harish Rajak1 et.al (93) 2010 study assess the efficacy of indole derivatives 
against sub-chronic inflammation, the cotton pellet granuloma model in rats 
employed compounds 1, 2 and 3 showed higher significant effect (𝑃 < 0.005) 
on reduced the granuloma formation while indomethacin greater significant 
effect (P< 0.05) compared to control. The 1, 2 and 3 showed Percentage 
inhibition of granuloma tissue formation (46.46%, 43.89% and 46.32% 
respectively) compared with indomethacin (54.20%). 
The m1k and the 1, 2 and 3 showed there is may no significant difference 
between this study findings and In Harish Rajak1 et.al, 2010 study findings.  
Non-steroidal anti-inflammatory drugs decrease the size of granuloma which 
results from cellular reaction by inhibiting granulocyte infiltration, preventing 
generation of collagen fibres and suppressing mucopolysaccharides (5). 
4.4. Membrane Stabilizing Activity Assay, in vitro study. 
The m1k exhibited membrane stabilization and it was effective in inhibiting 
the heat-induced haemolysis of erythrocyte membrane at different 
concentrations and its effectiveness was dose-dependent. The m1k and 
indomethacin showed the highest significant effect (P < 0.001) compared with 
control (See table: 3-6). 
The maximum percentage of inhibition haemolysis of membrane of m1k was 
98.66%, compared with indomethacin which showed 94.99 % inhibition 
haemolysis of membrane (See table: 3-7). 
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In Kumar M R, et.al (104) 2018 study membrane stabilizing assay of indole 
derivative 5c and 5h showed the  greater percentage of inhibition haemolysis 
of membrane (92.75% and 95.25% respectively).The m1k and 5a-I showed 
there is may no significant difference. 
In Abraham R et.al (105) 2018 study membrane stabilizing assay of indole 
derivative 4b and 4c showed greater percentage of inhibition haemolysis of 
membrane (95% and 96% respectively).The m1k and 4b and 4c showed there 
is may no significant difference. 
4.5. Acute Ulcerogenesis, in vivo study. 
The ulcerogenic effect of m1k compared with indomethacin was studied using 
acute ulecrogenesis methods. 
 The results revealed that, the m1k exhibited greater ulcerogenic liability 
(ulcer index =15) in comparison with indomethacin (Ulcer Index =7.99), (See 
table: 3-8). 
M1k and indomethacin showed a greater damage on gastric membrane that 
could be attributed to the high affinity to COX-1 over COX-2. 
In Amin N.H, et.al (106) 2018 study the ulcerogenic liability test of indole 
derivatives studied, the 4e and 4h exhibited moderate ulcerogenic liability 
(ulcer index =10 and 11.70 respectively) while indomethacin exhibited greater 
ulcerogenic liability (ulcer index =20). 
M1k exhibited greater ulcerogenic liability (ulcer index =15) in comparison 
with 4e and 4h (ulcer index =10 and 11.70 respectively), there is significant 
difference between this study findings and Amin N.H, et.al, 2018 study , may 
due to M1k has high affinity to COX-1 over COX-2. 
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In Abdellatif KRA et.al (102) 2017 study the ulcerogenic liability test of indole 
derivatives studied, the results revealed that, 13a, 13b, 13d and 13e exhibited 
lower ulcerogenic liability (ulcer index = 8.87, 6.40, 6.97 and 3.9 respectively) 
in comparison with indomethacin (Ulcer Index = 20.2), 
M1k exhibited greater ulcerogenic liability (ulcer index =15) in comparison 
with 13a, 13b, 13d and 13e exhibited moderate ulcerogenic liability (ulcer 
index = 8.87, 6.40, 6.97 and 3.9 respectively), there is significant difference 
between this study findings and Abdellatif KRA, et.al, 2017 study , may due 





























5. Conclusion and Recommendations 
1- 5.1. Conclusion. 
Results obtained in this study can be summarised as following:  
 M1k showed the highest affinity to COX2 (Affinity energy = -14.56 
kcal/mol), on molecular docking study compared to indomethacin, in silco. 
The m1k showed the highest significant effect (P<0.001) reduction in paw 
edema against carrageenan on carrageenan induced rat paw edema method 
compared to control, in vivo. 
The m1k showed higher anti-inflammatory activity percentage (77.2%) on 
carrageenan induced rat paw edema method compared to indomethacin. in 
vivo. 
The m1k showed the highest significant effect (𝑃 < 0.001) in reducing the 
granuloma formation on cotton pellet-induced granuloma method compared 
to control, in vivo. 
The m1k showed the highest anti-inflammatory activity percentage (60.93 %) 
on cotton pellet-induced granuloma method compared to indomethacin, in 
vivo. 
The m1k exhibited the highest significant effect (P < 0.001) in inhibiting the 
heat-induced haemolysis of erythrocyte membrane on membrane stabilizing 
activity assay compared to control, in vitro. 
The m1k showed the highest anti-inflammatory activity percentage (98.66%) 
on membrane stabilizing activity assay compared to indomethacin, in vitro. 
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The m1k exhibited higher ulcerogenic liability (ulcer index =15) on acute 
ulcerogenesis compared to indomethacin, in vivo. 
Finding from this study clearly suggests that the m1k possess significant anti-
inflammatory properties in both acute and sub-acute inflammation with high 
irritant to gastric mucosa as indicated by severity index., results indicate that 
m1k has a potent anti-inflammatory activity and the probable mechanism of 
this action may be due to its influence on the cyclooxygenase pathway, beside 
that it can interact with and stabilize human RBCs in the serum, and has ability 
to inhibit thermally-induced haemolysis of erythrocyte membrane such as 
indomethacin. 
2- 5.2 Recommendations 
1- Other experimental models must be studied. 
2- Determination of COX-2 selectivity of the m1k by assessing COX-2: COX-1 
inhibitory ratio using human whole blood assay. 
3- Mechanism of action of m1k may elucidated by COX-1/COX-2 inhibition 
colorimetric assay. 
4- More studies are needed on the ulcerogenic side effects of m1k. 
5- Assess the analgesic and antipyretic activities of m1k. 
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